- Q3 2026 revenues $16.6B, flat YoY
- Ex-COVID revenues up 7% operationally
- Launched/acquired products up 32% operationally
Pfizer reported Q3 2026 revenues of $16.6B, relatively flat YoY, but ex-COVID products grew 7% operationally. The company raised full-year revenue and EPS guidance. Cecile Guegan was appointed CFO effective Nov 1.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.